Brandon Bellows, PharmD, MS

  • Assistant Professor of Medical Sciences (in Medicine) at CUMC
Profile Headshot

Overview

Brandon Bellows received his PharmD and MS from the University of Utah, where he also completed a two-year post-doctoral fellowship in health economics and outcomes research. His research is focused on using computer simulations to estimate the clinical and cost effectiveness of healthcare interventions, particularly in hypertension and cardiovascular disease prevention, and inform implementation decisions. Dr. Bellows’ is currently supported by a career development award from the National Heart, Lung, and Blood Institute to compare the feasibility and cost effectiveness of implementing the intensive systolic blood pressure treatment goals from SPRINT at the local level in four distinct health systems.

Academic Appointments

  • Assistant Professor of Medical Sciences (in Medicine) at CUMC

Credentials & Experience

Education & Training

  • PharmD, 2010 University of Utah, School of Medicine
  • MS, 2014 University of Utah, School of Medicine
  • Fellowship: Department of Pharmacotherapy, University of Utah

Research

Dr. Bellows’ research uses epidemiology and computer simulation to understand the drivers of cardiovascular health across the life course. His research examines how the process of providing healthcare affects outcomes so that we can identify the most effective, cost-effective, and equitable strategies to prevent cardiovascular disease. He is funded by the National Institutes of Health and the American Heart Association.

Grants

  • 2022-2026
    NIH/NIA R01AG074989
    Cohen (PI), Bellows (site PI)
  • 2021-2026
    American Heart Association Health Equity Research Network on the Prevention of Hypertension
    Ogedegbe (PI)
  • 2018-2023
    NIH/NHLBI K01HL140170
    Bellows (PI)

Selected Publications

  1. Cohen LP, Isaza N, Hernandez I, Lewis GD, Ho JE, Fonarow GC, Kazi DS, Bellows BK. Cost-effectiveness of SGLT2 inhibitors for the treatment of heart failure with preserved ejection fraction. JAMA Cardiol. 2023 May 1;8(5):419-428. PMID: 36870047.
  2. Bryant KB, Rao AS, Cohen LP, DanDan N, Kronish IM, Barai N, Fontil V, Zhang Y, Moran AE, Bellows BK. Effectiveness and cost-effectiveness of team-based care strategies for hypertension: A meta-analysis and simulation study. Hypertension. 2023 Mar 8. PMID: 36883454.
  3. Birger M, Kaldjian A, Roth G, Moran AE, Dieleman J, Bellows BK. Health care spending on cardiovascular disease and cardiovascular risk factors in the United States: 1996-2016. Circulation. 2021 Jul 27;144(4):271-282. PMID: 33926203.
  4. Byrant KB, Moran AE, Kazi DS, Zhang Y, Penko J, Ruiz-Negrón N, Coxson P, Blyler CA, Lynch K, Cohen LP, Tajeu GS, Fontil V, Moy NB, Ebinger JE, Rader F, Bibbins-Domingo K, Bellows BK. Cost-effectiveness of blood pressure reduction by pharmacists in Black barbershops. Circulation. 2021 Jun 15;143(24):2384-2394. PMID: 33855861.
  5. Bress AP*, Bellows BK*, King JB, Hess R, Beddhu S, Zhang Z, Berlowitz DR, Conroy MB, Fine L, Oparil S, Morisky DE, Kazis LE, Ruiz-Negrón N, Powell J, Tamariz L, Whittle J, Wright J, Supiano MA, Cheung AK, Weintraub WS, Moran AE, for the SPRINT Research Group. Cost-effectiveness of intensive versus standard blood pressure control. N Engl J Med. 2017 Aug 24;377(8):745-755. PMID: 28834469. *Co-first authors
  6. King JB, Shah RU, Bress A, Nelson RE, Bellows BK. Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction. JACC Heart Fail. 2016 May;4(5):392-402.
  7. Bellows BK, Tak CR, Sanders JN, Turok DK, Schwarz EB. Cost-effectiveness of emergency contraception options over one year. Am J Obstet Gynecol. 2018;218(5):508.e1-9.
  8. Bellows BK, Nelson RE, Oderda GM, LaFleur J. Long-term cost-effectiveness of initiating treatment for diabetic painful neuropathy with pregabalin, duloxetine, gabapentin, or desipramine. Pain. 2016 Jan;157(1):203-213.